{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T22:44:56Z","timestamp":1790808296050,"version":"4.1.0"},"reference-count":25,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,12,1]],"date-time":"2020-12-01T00:00:00Z","timestamp":1606780800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2020,12,2]],"date-time":"2020-12-02T00:00:00Z","timestamp":1606867200000},"content-version":"vor","delay-in-days":1,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100004622","name":"KWF Kankerbestrijding","doi-asserted-by":"publisher","award":["AMC2014-6782"],"award-info":[{"award-number":["AMC2014-6782"]}],"id":[{"id":"10.13039\/501100004622","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cancer"],"published-print":{"date-parts":[[2020,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Pancreatic ductal adenocarcinoma (PDAC) is a grim disease with high mortality rates. Increased macrophage influx in PDAC is a common hallmark and associated with poor prognosis. Macrophages have high cellular plasticity, which can differentiate into both anti- and pro-tumorigenic properties. Here, we investigated how na\u00efve (M0) macrophages differ from other macrophages in their anti-tumorigenic activities.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>In vitro BrdU proliferation and Annexin V cell death analyses were performed on PANC-1 and MIA PaCa-2 PDAC cell lines exposed to conditioned medium of different macrophage subsets. Macrophage secreted factors were measured by transcript analysis and ELISA. Therapeutic antibodies were used to functionally establish the impact of the identified cytokine on PDAC proliferation.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Proliferation and cell death assays revealed that only M0 macrophages harbor anti-tumorigenic activities and that M1, M2, and TAMs do not. mRNA analysis and ELISA results suggested TNF-\u03b1 as a potential candidate to mediate M0 macrophage induced cell death. To demonstrate the importance of TNF-\u03b1 in M0 macrophage-induced cell death, PANC-1 and MIA PaCa-2 cell-lines were exposed to M0 macrophage conditioned medium in the presence of the TNF-\u03b1 inhibitor Infliximab, which effectively diminished the anti-tumor activities of M0 macrophages.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Newly tumor-infiltrated naive M0 macrophages exert anti-tumorigenic activities via TNF-\u03b1 secretion. Their subsequent differentiation into either M1, M2, or TAM subsets reduces TNF-\u03b1 levels, thereby abolishing their cytotoxic activity on PDAC cells. These data suggest that reestablishing TNF-\u03b1 secretion in differentiated macrophages might yield a therapeutic benefit.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12885-020-07697-1","type":"journal-article","created":{"date-parts":[[2020,12,2]],"date-time":"2020-12-02T07:03:16Z","timestamp":1606892596000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":40,"title":["Early macrophage infiltrates impair pancreatic cancer cell growth by TNF-\u03b1 secretion"],"prefix":"10.1186","volume":"20","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3961-5603","authenticated-orcid":false,"given":"Cansu","family":"Tekin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hella L.","family":"Aberson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maarten F.","family":"Bijlsma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C. Arnold","family":"Spek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,12,2]]},"reference":[{"key":"7697_CR1","doi-asserted-by":"publisher","first-page":"v56","DOI":"10.1093\/annonc\/mdv295","volume":"26","author":"M Ducreux","year":"2015","unstructured":"Ducreux M, Cuhna AS, Caramella C, Hollebecque A, Burtin P, Go\u00e9r\u00e9 D, et al. Cancer of the pancreas: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2015;26:v56\u201368.","journal-title":"Ann Oncol"},{"key":"7697_CR2","doi-asserted-by":"publisher","first-page":"7","DOI":"10.3322\/caac.21551","volume":"69","author":"RL Siegel","year":"2019","unstructured":"Siegel RL, Miller KD, Jemal A. Cancer statistics, 2019. CA Cancer J Clin. 2019;69:7\u201334.","journal-title":"CA Cancer J Clin"},{"key":"7697_CR3","doi-asserted-by":"publisher","first-page":"122","DOI":"10.3390\/cancers9090122","volume":"9","author":"N Gaianigo","year":"2017","unstructured":"Gaianigo N, Melisi D, Carbone C. EMT and treatment resistance in pancreatic cancer. Cancers (Basel). 2017;9:122.","journal-title":"Cancers (Basel)"},{"key":"7697_CR4","doi-asserted-by":"publisher","first-page":"958","DOI":"10.1038\/nri2448","volume":"8","author":"DM Mosser","year":"2008","unstructured":"Mosser DM, Edwards JP. Exploring the full spectrum of macrophage activation. Nat Rev Immunol. 2008;8:958\u201369.","journal-title":"Nat Rev Immunol"},{"key":"7697_CR5","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1007\/s10555-006-9001-7","volume":"25","author":"A Mantovani","year":"2006","unstructured":"Mantovani A, Schioppa T, Porta C, Allavena P, Sica A. Role of tumor-associated macrophages in tumor progression and invasion. Cancer Metastasis Rev. 2006;25:315\u201322.","journal-title":"Cancer Metastasis Rev"},{"key":"7697_CR6","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1038\/nrc1256","volume":"4","author":"JW Pollard","year":"2004","unstructured":"Pollard JW. Tumour-educated macrophages promote tumour progression and metastasis. Nat Rev Cancer. 2004;4:71\u20138.","journal-title":"Nat Rev Cancer"},{"key":"7697_CR7","doi-asserted-by":"publisher","first-page":"462","DOI":"10.1016\/j.ccell.2015.02.015","volume":"27","author":"B Ruffell","year":"2015","unstructured":"Ruffell B, Coussens LM. Macrophages and therapeutic resistance in cancer. Cancer Cell. 2015;27:462\u201372.","journal-title":"Cancer Cell"},{"key":"7697_CR8","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1016\/j.cell.2010.03.014","volume":"141","author":"B-Z Qian","year":"2010","unstructured":"Qian B-Z, Pollard JW. Macrophage diversity enhances tumor progression and metastasis. Cell. 2010;141:39\u201351.","journal-title":"Cell."},{"key":"7697_CR9","doi-asserted-by":"crossref","unstructured":"Tekin C, Aberson HL, Waasdorp C, Hooijer GKJ, de Boer OJ, Dijk F, et al. Macrophage-secreted MMP9 induces mesenchymal transition in pancreatic cancer cells via PAR1 activation. Cell Oncol. 2020.","DOI":"10.1007\/s13402-020-00549-x"},{"key":"7697_CR10","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1016\/j.semcancer.2011.12.005","volume":"22","author":"FR Balkwill","year":"2012","unstructured":"Balkwill FR, Mantovani A. Cancer-related inflammation: common themes and therapeutic opportunities. Semin Cancer Biol. 2012;22:33\u201340.","journal-title":"Semin Cancer Biol"},{"key":"7697_CR11","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3389\/fimmu.2014.00491","volume":"5","author":"G Arango Duque","year":"2014","unstructured":"Arango Duque G, Descoteaux A. Macrophage cytokines: involvement in immunity and infectious diseases. Front Immunol. 2014;5:1\u201312.","journal-title":"Front Immunol"},{"key":"7697_CR12","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1002\/ibd.21818","volume":"18","author":"ACW Vos","year":"2012","unstructured":"Vos ACW, Wildenberg ME, Arijs I, Duijvestein M, Verhaar AP, De Hertogh G, et al. Regulatory macrophages induced by infliximab are involved in healing in vivo and in vitro. Inflamm Bowel Dis. 2012;18:401\u20138.","journal-title":"Inflamm Bowel Dis"},{"key":"7697_CR13","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1016\/j.pharmthera.2019.05.012","volume":"201","author":"ML Stone","year":"2019","unstructured":"Stone ML, Beatty GL. Cellular determinants and therapeutic implications of inflammation in pancreatic cancer. Pharmacol Ther. 2019;201:202\u201313.","journal-title":"Pharmacol Ther"},{"key":"7697_CR14","doi-asserted-by":"publisher","first-page":"2294","DOI":"10.1002\/ijc.28726","volume":"135","author":"KCS Queiroz","year":"2014","unstructured":"Queiroz KCS, Shi K, Duitman J, Aberson HL, Wilmink JW, Van Noesel CJM, et al. Protease-activated receptor-1 drives pancreatic cancer progression and chemoresistance. Int J Cancer. 2014;135:2294\u2013304.","journal-title":"Int J Cancer"},{"key":"7697_CR15","doi-asserted-by":"publisher","first-page":"3404","DOI":"10.1158\/1078-0432.CCR-13-0525","volume":"19","author":"DE Sanford","year":"2013","unstructured":"Sanford DE, Belt BA, Panni RZ, Mayer A, Deshpande AD, Carpenter D, et al. Inflammatory monocyte mobilization decreases patient survival in pancreatic cancer: a role for targeting the CCL2\/CCR2 axis. Clin Cancer Res. 2013;19:3404\u201315.","journal-title":"Clin Cancer Res"},{"key":"7697_CR16","doi-asserted-by":"publisher","first-page":"1128","DOI":"10.1158\/0008-5472.CAN-12-2731","volume":"73","author":"JB Mitchem","year":"2013","unstructured":"Mitchem JB, Brennan DJ, Knolhoff BL, Belt BA, Zhu Y, Sanford DE, et al. Targeting tumor-infiltrating macrophages decreases tumor-initiating cells, relieves immunosuppression, and improves chemotherapeutic responses. Cancer Res. 2013;73:1128\u201341.","journal-title":"Cancer Res"},{"key":"7697_CR17","doi-asserted-by":"publisher","first-page":"318","DOI":"10.4132\/jptm.2015.06.01","volume":"49","author":"KY Jung","year":"2015","unstructured":"Jung KY, Cho SW, Kim YA, Kim D, Oh B-C, Park DJ, et al. Cancers with higher density of tumor-associated macrophages were associated with poor survival rates. J Pathol Transl Med. 2015;49:318\u201324.","journal-title":"J Pathol Transl Med"},{"key":"7697_CR18","doi-asserted-by":"publisher","first-page":"104","DOI":"10.3892\/ijo.2017.3996","volume":"51","author":"T Lindsten","year":"2017","unstructured":"Lindsten T, Hedbrant A, Ramberg A, Wijkander J, Solterbeck A, Eriksson M, et al. Effect of macrophages on breast cancer cell proliferation, and on expression of hormone receptors, uPAR and HER-2. Int J Oncol. 2017;51:104\u201314.","journal-title":"Int J Oncol"},{"key":"7697_CR19","doi-asserted-by":"publisher","first-page":"e50946","DOI":"10.1371\/annotation\/7c7feaa4-b9c5-4cd0-914b-b72499a16365","volume":"7","author":"ZQ wen","year":"2012","unstructured":"wen ZQ, Liu L, yang GC, shan SH, hui ZY, ze WX, et al. Prognostic significance of tumor-associated macrophages in solid tumor: a meta-analysis of the literature. Hoque MO, editor. PLoS One. 2012;7:e50946.","journal-title":"PLoS One"},{"key":"7697_CR20","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1016\/j.canlet.2015.11.049","volume":"381","author":"A Habtezion","year":"2016","unstructured":"Habtezion A, Edderkaoui M, Pandol SJ. Macrophages and pancreatic ductal adenocarcinoma. Cancer Lett. 2016;381:211\u20136.","journal-title":"Cancer Lett"},{"key":"7697_CR21","doi-asserted-by":"publisher","first-page":"887","DOI":"10.1038\/nrd.2018.169","volume":"17","author":"L Cassetta","year":"2018","unstructured":"Cassetta L, Pollard JW. Targeting macrophages: therapeutic approaches in cancer. Nat Rev Drug Discov. 2018;17:887\u2013904.","journal-title":"Nat Rev Drug Discov"},{"key":"7697_CR22","doi-asserted-by":"publisher","first-page":"2475","DOI":"10.1038\/onc.2010.619","volume":"30","author":"TJ Standiford","year":"2011","unstructured":"Standiford TJ, Kuick R, Bhan U, Chen J, Newstead M, Keshamouni VG. TGF-\u0392-induced IRAK-M expression in tumor-associated macrophages regulates lung tumor growth. Oncogene. 2011;30:2475\u201384.","journal-title":"Oncogene."},{"key":"7697_CR23","doi-asserted-by":"publisher","first-page":"3032","DOI":"10.4049\/jimmunol.174.5.3032","volume":"174","author":"C del Fresno","year":"2005","unstructured":"del Fresno C, Otero K, G\u00f3mez-Garc\u00eda L, Gonz\u00e1lez-Le\u00f3n MC, Soler-Ranger L, Fuentes-Prior P, et al. Tumor cells deactivate human monocytes by up-regulating IL-1 receptor associated kinase-M expression via CD44 and TLR4. J Immunol. 2005;174:3032\u201340.","journal-title":"J Immunol"},{"key":"7697_CR24","doi-asserted-by":"publisher","first-page":"894","DOI":"10.3390\/ijms19030894","volume":"19","author":"A Lescoat","year":"2018","unstructured":"Lescoat A, Ballerie A, Augagneur Y, Morzadec C, Vernhet L, Fardel O, et al. Distinct properties of human M-CSF and GM-CSF monocyte-derived macrophages to simulate pathological lung conditions in vitro: application to systemic and inflammatory disorders with pulmonary involvement. Int J Mol Sci. 2018;19:894.","journal-title":"Int J Mol Sci"},{"key":"7697_CR25","doi-asserted-by":"publisher","first-page":"1114","DOI":"10.1038\/nature09515","volume":"467","author":"S Yachida","year":"2010","unstructured":"Yachida S, Jones S, Bozic I, Antal T, Leary R, Fu B, et al. Distant metastasis occurs late during the genetic evolution of pancreatic cancer. Nature. 2010;467:1114\u20137.","journal-title":"Nature."}],"container-title":["BMC Cancer"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-020-07697-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s12885-020-07697-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-020-07697-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,12,2]],"date-time":"2020-12-02T23:44:49Z","timestamp":1606952689000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmccancer.biomedcentral.com\/articles\/10.1186\/s12885-020-07697-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,12]]},"references-count":25,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["7697"],"URL":"https:\/\/doi.org\/10.1186\/s12885-020-07697-1","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-54015\/v1","asserted-by":"object"},{"id-type":"doi","id":"10.21203\/rs.3.rs-54015\/v3","asserted-by":"object"},{"id-type":"doi","id":"10.21203\/rs.3.rs-54015\/v2","asserted-by":"object"}]},"ISSN":["1471-2407"],"issn-type":[{"value":"1471-2407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,12]]},"assertion":[{"value":"4 August 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 November 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 December 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Whole blood was collected from a single healthy volunteer following institutional standard operating protocol and under the Medical Ethics Review Committee\u2019s approval.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"MFB has received research funding from Celgene and has acted as a consultant for Servier. However, these parties were not involved in the study design, collection, or drafting of this manuscript.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"1183"}}